Name of this trial: Ideate-Prostate-01
What type of cancer is this for? Prostate Cancer
Who is this trial for? Patients with metastatic castration-resistant prostate cancer
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06925737
Brief summary of this trial: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Need to know: Must have had progression of disease while on androgen deprivation therapy (ADT)(or post bilateral orchiectomy) within 6 months prior to entering study. Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]